Abuse, Drug, Pain
Conditions
Keywords
Cannabis, Analgesia, Pain, THC, Terpenes
Brief summary
The purpose of this research is to assess the analgesic and subjective effects of terpenes administered alone and in combination of THC.
Detailed description
The overall aim of this placebo-controlled study is to examine dose-dependent analgesia, intoxication, abuse liability, and pharmacokinetics of ecologically relevant doses of vaporized myrcene and beta-caryophyllene administered alone or with vaporized THC.
Interventions
DRUGLow THC
Vaporized THC (5 mg)
DRUGHigh THC
Vaporized THC (15 mg)
DRUGLow Myrcene
Vaporized Myrcene (0.5 mg)
DRUGHigh Myrcene
Vaporized Myrcene (12.0 mg)
DRUGLow Beta-Caryophyllene
Vaporized Beta-Caryophyllene (0.5 mg)
DRUGHigh Beta-Caryophyllene
Vaporized Beta-Caryophyllene (7.5 mg)
DRUGPlacebo
Vaporized Placebo
Sponsors
University of California, Los Angeles
National Center for Complementary and Integrative Health (NCCIH)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Intervention model description
This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.
Eligibility
Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or non-pregnant female aged 21-55 years * Report non-medical use of cannabis 1-7 days per week over the 1 month prior to screening * Not currently seeking treatment for cannabis use * Urine test positive for recent cannabis use * Have a Body Mass Index from 18.5 - 34kg/m2. * Able to perform all study procedures * Must be using a contraceptive method (hormonal or barrier methods)
Exclusion criteria
* Meeting DSM-V criteria for any substance use disorder other than nicotine, caffeine, or mild CUD * Report using other illicit drugs in the prior 4 weeks * • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures. * Current licit use of cannabis primarily for medical purposes, prescription analgesics, or any medications that may affect study outcomes * Current pain * Pregnancy is exclusionary due to the possible effects of the study medication on fetal development. * History of an allergic reaction or adverse reaction to cannabis is exclusionary. * History of respiratory illness or current respiratory illness * History of seizure disorder or current seizure disorder * Insensitivity to the cold water stimulus of the Cold Pressor Test * Currently enrolled in another research protocol * Current major Axis 1 disorders (mood, anxiety, or psychotic disorder) * Not using a contraceptive method (hormonal or barrier methods) * The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analgesia as measured using the Cold Pressor Test | 7 hours | Pain threshold and pain tolerance assessed using the Cold Pressor Test |
| Subject-rated drug effects of abuse liability | 7 hours | Subject ratings of "Good Drug Effect" as measured using a visual analog scale (1-100 mm) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subject-rated drug effects of intoxication | 7 hours | Subject ratings of "High" as measured using a visual analog scale (1-100 mm) |
| Subjective ratings of pain | 7 hours | Subject ratings of Painfulness and Bothersomeness of the Cold Pressor Test |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORZiva Cooper, PhD
University of California, Los Angeles
Outcome results
None listed